Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Adicionar filtros








Intervalo de ano
1.
Braz. j. med. biol. res ; 27(1): 91-4, jan. 1994. tab
Artigo em Inglês | LILACS | ID: lil-136497

RESUMO

Rhodium (II) trifluoracetate (TFARh), rhodium (II) trifluoracetate adduct with sulfadiazine (TFARh.Sd) and rhodium (II) acetate adduct with sulfisoxazole (RhSx) were tested in mice for acute toxicity, antitumoral activity against Ehrlich ascites carcinoma and for viability of Ehrlich tumor cells in culture. At ip doses up to 60 µmg/kg (40-70 and 59 mg/kg, respectively), these coumpounds had no toxic effects up to 14 days. At ip doses of 10 µmol Kg-1 day-1 for 5 days, TFARh and TFARh.Sd significantly increased the survival rate of mice bearing Ehrlich ascites cells (probability of survival to the end of 34th day, controls = 0.23, TFARh = 0.85, TFARh.Sd = 0.74). No significant effect was observed for RhSx. In vitro, these rhodium complexes at 40 µM significantly increased the number of dead cells in cultured Ehrlich tumor cells


Assuntos
Camundongos , Protocolos de Quimioterapia Combinada Antineoplásica/farmacologia , Carcinoma de Ehrlich/tratamento farmacológico , Técnicas In Vitro , Ródio/farmacologia , Acetatos/administração & dosagem , Carcinoma de Ehrlich/mortalidade , Camundongos Endogâmicos BALB C , Sulfadiazina/administração & dosagem , Sulfisoxazol/administração & dosagem , Fatores de Tempo , Ácido Trifluoracético/administração & dosagem
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA